Nuvo Research

NRI-T

Analysis and Opinions about NRI-T

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
December 2, 2016

(A Top Pick Oct 8/15. Up 18.06%.) A nice little company he discovered a few years ago. They had a big fight with their US distributor, and won $50 million. They got a new distribution for their topical cream and it took off. Had a bad 3rd quarter. They have a ton of cash, so there is room for M&A and new products.

Show full opinionHide full opinion
Nuvo Research (NRI-T)
December 2, 2016

(A Top Pick Oct 8/15. Up 18.06%.) A nice little company he discovered a few years ago. They had a big fight with their US distributor, and won $50 million. They got a new distribution for their topical cream and it took off. Had a bad 3rd quarter. They have a ton of cash, so there is room for M&A and new products.

COMMENT
COMMENT
December 4, 2015

Has been involved in this name for about 1.5 years and has done well on it. They have 2 sides to their business. One produces a topical drug called Pennsaid, which is licensed to do sales in the US. The other side is that they are developing drugs, particularly in allergies. The stock plunged from $10-$5 because they had negative results. They have $50 million in cash. He likes this company.

Show full opinionHide full opinion
Nuvo Research (NRI-T)
December 4, 2015

Has been involved in this name for about 1.5 years and has done well on it. They have 2 sides to their business. One produces a topical drug called Pennsaid, which is licensed to do sales in the US. The other side is that they are developing drugs, particularly in allergies. The stock plunged from $10-$5 because they had negative results. They have $50 million in cash. He likes this company.

TOP PICK
TOP PICK
October 8, 2015

One side is a biotech company to develop new drugs and the other is a specialty pharma business. The problem is that they have $50 million in cash and $75 million capitalization. He thinks they will separate the companies. It is worth $12 per share unless they hit it big in the drug side.

Show full opinionHide full opinion
Nuvo Research (NRI-T)
October 8, 2015

One side is a biotech company to develop new drugs and the other is a specialty pharma business. The problem is that they have $50 million in cash and $75 million capitalization. He thinks they will separate the companies. It is worth $12 per share unless they hit it big in the drug side.

COMMENT
COMMENT
January 28, 2015

A drug company that has a commercial product that is selling. Also has a very interesting allergy drug they are testing in Germany. If they can come up with a really effective treatment, this stock is going to go a lot higher. Results from phase 2 clinical trials are out in a week or 2. He has done extremely well in this name. Be a little bit cautious until you see what the clinical results are, but this is a classic case of “buy on rumour and sell on news”. Have a pile of cash so the downside is pretty limited. If it works out, the stock is going to go much higher, but if it doesn’t the downside could be $6 only.

Show full opinionHide full opinion
Nuvo Research (NRI-T)
January 28, 2015

A drug company that has a commercial product that is selling. Also has a very interesting allergy drug they are testing in Germany. If they can come up with a really effective treatment, this stock is going to go a lot higher. Results from phase 2 clinical trials are out in a week or 2. He has done extremely well in this name. Be a little bit cautious until you see what the clinical results are, but this is a classic case of “buy on rumour and sell on news”. Have a pile of cash so the downside is pretty limited. If it works out, the stock is going to go much higher, but if it doesn’t the downside could be $6 only.

DON'T BUY
DON'T BUY
October 4, 2011
After he went to the AGM he decided he was not interested. They don’t manage to do what they say they are going to do. Can’t seem to gain traction. Concerned about a stock consolidation in the future.
Show full opinionHide full opinion
Nuvo Research (NRI-T)
October 4, 2011
After he went to the AGM he decided he was not interested. They don’t manage to do what they say they are going to do. Can’t seem to gain traction. Concerned about a stock consolidation in the future.
DON'T BUY
DON'T BUY
January 26, 2009
(Market Call Minute.) Ranks 104 and will have difficulty performing.
Show full opinionHide full opinion
Nuvo Research (NRI-T)
January 26, 2009
(Market Call Minute.) Ranks 104 and will have difficulty performing.
BUY
BUY
January 12, 2007
Just got approval from the FDA to sell their arthritic medication. Likes this sector. The stock has built a base followed by a higher base over the last few years. This should be fine, but have stop at the higher base level.
Show full opinionHide full opinion
Nuvo Research (NRI-T)
January 12, 2007
Just got approval from the FDA to sell their arthritic medication. Likes this sector. The stock has built a base followed by a higher base over the last few years. This should be fine, but have stop at the higher base level.
WATCH
WATCH
March 13, 2006
Estimates have been shaved back 10% in the past 90 days. Their work on arthritic drugs is interesting and phase 3 is looking good. They are watching it. If the drug is approved it would be positive for the company.
Show full opinionHide full opinion
Nuvo Research (NRI-T)
March 13, 2006
Estimates have been shaved back 10% in the past 90 days. Their work on arthritic drugs is interesting and phase 3 is looking good. They are watching it. If the drug is approved it would be positive for the company.
Showing 1 to 8 of 8 entries
  • «
  • 1
  • »

Nuvo Research(NRI-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Nuvo Research is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Nuvo Research(NRI-T) Frequently Asked Questions

What is Nuvo Research stock symbol?

Nuvo Research is a Canadian stock, trading under the symbol NRI-T on the Toronto Stock Exchange (NRI-CT). It is usually referred to as TSX:NRI or NRI-T

Is Nuvo Research a buy or a sell?

In the last year, there was no coverage of Nuvo Research published on Stockchase.

Is Nuvo Research a good investment or a top pick?

Nuvo Research was recommended as a Top Pick by Fabrice Taylor on 2016-12-02. Read the latest stock experts ratings for Nuvo Research.

Why is Nuvo Research stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Nuvo Research worth watching?

0 stock analysts on Stockchase covered Nuvo Research In the last year. It is a trending stock that is worth watching.

What is Nuvo Research stock price?

On 2020-10-29, Nuvo Research (NRI-T) stock closed at a price of $0.81.